At the news
? NEUTRALIMPACT 3/10 8-K filed Mar 4, 2026 at 16:02 ET
Vir Biotechnology appointed CEO Marianne De Backer to the additional role of President. This is an internal leadership expansion with no immediate financial impact or executive departure.
- Marianne De Backer, current CEO and principal executive officer, was appointed to the additional role of President on March 4, 2026
- No executive departures were reported
- No compensation details were disclosed in the filing
- The appointment reflects a consolidation of leadership roles under the existing CEO
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access